- PRGF - ENDORET®
- Medical specialties
- BTI APNIA®
- Diagnosis
- Treatment

PRGF - ENDORET® technology represents an advanced biomedical, 100% autologous solution in ophthalmology. Its use as eye drops optimises restoration of the corneal epithelium and stimulates tissue healing, improving the prognosis of persistent epithelial defects and moderate to severe dry eye disease. In addition, its fibrin-based surgical formulations provide a fully resorbable physical scaffold that promotes effective tissue regeneration.


Highly effective in the treatment of Persistent Epithelial Defects (PEDs) of diverse aetiologies, including neurogenic, iatrogenic and burn-related causes, achieving complete healing in 85% of patients in a mean of 10.9 weeks, in cases where mean progression with other conventional treatments was 26.7 weeks.
Successfully restores corneal epithelial integrity even in patients in whom previous treatment with conventional autologous serum had not been effective.
Directly reduces inflammation in ocular tissue, minimising the need for chronic adjunctive therapies such as corticosteroids and ciclosporin.
Its high antifibrotic potential supports corneal transparency and actively protects against the development of corneal scarring and leucomas.
Use as a culture medium for stem cell expansion (for example, limbal cells)
Texto de ejemplo
Enables a complete course of treatment lasting up to 6 months.
Safe long-term storage by freezing at -20°C.
Each individual single-dose device/dispenser remains stable for up to 72 hours at room temperature, facilitating daily use anywhere without the need for constant refrigeration.
Rapid and straightforward preparation procedure, entirely free from dilution steps.

Through a single standardised protocol, the specialist can obtain up to 4 different formulations, including liquid plasma and clot, for use as a graft or injectable.
Allows preparation of an autologous fibrin membrane distinguished by being suturable, resistant, easy to handle and completely resorbable by the body.

Yes. Whereas other generic PRP eye drops may present variable platelet concentrations and non-standardised processing, PRGF - ENDORET® technology is based on strictly defined and validated protocols. This guarantees an optimal concentration of platelets and growth factors, directly influencing the final efficacy of treatment. In addition, its preparation method ensures a formulation completely free of leucocytes, removing components that promote pain, inflammation or fibrin degradation, thereby offering a high level of safety and clinical reproducibility.
The ocular surgery kit based on PRGF - ENDORET® technology allows a 100% autologous fibrin membrane to be prepared during the same surgical procedure, using the patient’s own blood. As a purely endogenous product, it offers absolute biocompatibility, with no risk of immunological rejection or reported adverse reactions. In the surgical setting, this three-dimensional matrix is distinguished by its mechanical resistance, suturability, ease of handling for the specialist and complete resorbability by the body, acting as an ideal scaffold that regulates the progressive release of proteins in order to accelerate the natural regeneration of ocular tissue.
The amniotic membrane is an allogeneic tissue (obtained from an external donor) which, although effective, involves a complex preservation process and a minimal latent risk of pathogen transmission or immunological rejection. By contrast, the fibrin membrane produced with PRGF-ENDORET® technology is 100% autologous (from the patient), is moulded to the exact required dimensions during the surgical procedure itself, and offers absolute biocompatibility, accelerating natural regeneration without any risk of rejection.
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
Texto de ejemplo
¡Gracias!